Cite
Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
MLA
Schuster, Stephen J., et al. “Comparative Efficacy of Tisagenlecleucel and Lisocabtagene Maraleucel among Adults with Relapsed/Refractory Large B-Cell Lymphomas: An Indirect Treatment Comparison.” Leukemia & Lymphoma, vol. 63, no. 4, Apr. 2022, pp. 845–54. EBSCOhost, https://doi.org/10.1080/10428194.2021.2010069.
APA
Schuster, S. J., Zhang, J., Yang, H., Agarwal, A., Tang, W., Martinez-Prieto, M., Bollu, V., Kuzan, D., Maziarz, R. T., & Kersten, M. J. (2022). Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. Leukemia & Lymphoma, 63(4), 845–854. https://doi.org/10.1080/10428194.2021.2010069
Chicago
Schuster, Stephen J., Jie Zhang, Hongbo Yang, Abhijit Agarwal, Wenxi Tang, Marcela Martinez-Prieto, Vamsi Bollu, David Kuzan, Richard T. Maziarz, and Marie José Kersten. 2022. “Comparative Efficacy of Tisagenlecleucel and Lisocabtagene Maraleucel among Adults with Relapsed/Refractory Large B-Cell Lymphomas: An Indirect Treatment Comparison.” Leukemia & Lymphoma 63 (4): 845–54. doi:10.1080/10428194.2021.2010069.